German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: Results from the PRISMA study

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2405-2410

  Seifert, Harald ^a   Dalhoff, Axel ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Anaerobes; Broth microdilution; Multicentre study; Surveillance

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; ERTAPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; SULTAMICILLIN;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES CACCAE; BACTEROIDES DISTASONIS; BACTEROIDES EGGERTHII; BACTEROIDES FRAGILIS; BACTEROIDES MERDAE; BACTEROIDES OVATUS; BACTEROIDES SPLANCHNICUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; BROTH DILUTION; CHILD; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRESCHOOL CHILD; PREVOTELLA; PREVOTELLA BIVIA; PREVOTELLA BUCCAE; PREVOTELLA DISIENS; PREVOTELLA LOESCHEII; PREVOTELLA MELANINOGENICA; PREVOTELLA ORALIS; PREVOTELLA ORIS; SCHOOL CHILD; SPECIES IDENTIFICATION;

ABDOMEN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEROIDACEAE INFECTIONS; BACTEROIDES FRAGILIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; GERMANY; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVOTELLA; YOUNG ADULT;

EID: 77957858518     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq321     Document Type: Article

References (18)

1. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9: 475-88.
2. Betriu C, Rodriguez-Avial I, Gomez M et al. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6 year period (1997-2002). Diagn Microbiol Infect Dis 2005; 53: 221-3.
3. Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of B. fragilis group: report and analysis of trends for 1997-2004: a US survey. Antimicrob Agents Chemother 2007; 51: 1649-55.
4. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-64.
5. Snydman DR, Jacobus NV, McDermott LA et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010; 50 Suppl 1: S26-33.
6. Liu CY, Huang YT, Liao CH et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008; 52: 3161-8.
7. Wybo I, Piérard D, Verschraegen I et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007; 59: 132-9.
8. Nagy E, Urbán E, Nord CE; on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: twenty years of experience. Clin Microbiol Infect 2010; doi:10.1111/j.1469-0691.2010.03256.x.
9. Dalhoff A. In vitro activities of quinolones. Exp Opin Invest Drugs 1999; 8: 123-37.
10. Solomkin J, Zhao YP, Ma EL et al. DRAGON Study Team: moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34: 439-45.
11. Weiss G, Reimnitz P, Hampel B et al. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother 2009; 21: 170-80.
12. Malangoni MA, Song J, Herrington J et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204-11.
13. Deutsches Institut für Normung e.V. (DIN), Normenausschuss Medizin (NAMed). Medical Microbiology. Susceptibility Testing of Microbial Pathogens to Antimicrobial Agents. DIN 58940, Part 83: Microdilution. Special Requirements for Testing of Strictly Anaerobic Bacteria. Germany: Beuth Verlag, 2002.
14. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical Breakpoints. http://www.eucast.org/clinical_breakpoints/ (19 July 2010, date last accessed).
15. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
16. Papaparaskevas J, Pantazatou A, Katsandri A et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 2008; 62: 137-41.
17. Oteo-Iglesias J, Alos JI, Gomez-Garces JL. Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group. J Antimicrob Chemother 2002; 50: 1055-7.
18. Nguyen MH, Yu VL, Morris AJ et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteraemia: findings of a multicentre prospective observational trial. Clin Infect Dis 2000; 30: 870-6.